Aptorum Group Net Income Applicable To Common Shares Over Time
| APM Stock | USD 0.81 0.07 9.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aptorum Group Performance and Aptorum Group Correlation. Will Biotechnology sector continue expanding? Could Aptorum diversify its offerings? Factors like these will boost the valuation of Aptorum Group. If investors know Aptorum will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Aptorum Group data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Aptorum Group is measured differently than its book value, which is the value of Aptorum that is recorded on the company's balance sheet. Investors also form their own opinion of Aptorum Group's value that differs from its market value or its book value, called intrinsic value, which is Aptorum Group's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Aptorum Group's market value can be influenced by many factors that don't directly affect Aptorum Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Aptorum Group's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Aptorum Group represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Aptorum Group's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Aptorum Group and related stocks such as Marker Therapeutics, Mustang Bio, and Cingulate Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRKR | 1.5 M | 1.5 M | 1.5 M | 1.5 M | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (41.9 M) | (41.9 M) | (41.9 M) | (37.7 M) | (39.6 M) |
| MBIO | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (5.4 M) | (12.7 M) | (31.3 M) | (30.7 M) | (46.4 M) | (60 M) | (66.4 M) | (77.5 M) | (77.5 M) | (77.5 M) | (69.8 M) | (66.3 M) |
| CING | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (7.2 M) | (20.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (15.9 M) | (16.7 M) |
| CLRB | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (8.1 M) | (5.5 M) | (9.4 M) | (15 M) | (15.5 M) | (14.1 M) | (15.1 M) | (24.1 M) | (28.6 M) | (28.6 M) | (28.6 M) | (25.7 M) | (24.5 M) |
| IMRN | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (3.4 M) | (7.1 M) | (6.8 M) | (3 M) | (4.7 M) | (2.9 M) | (8.4 M) | (2.9 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.4 M) | (3.6 M) |
| AEON | 137.1 M | 137.1 M | 137.1 M | 137.1 M | 137.1 M | 137.1 M | 137.1 M | 137.1 M | 137.1 M | 137.1 M | (50.2 M) | (55.6 M) | (52.6 M) | (52.6 M) | (52.6 M) | (47.3 M) | (44.9 M) |
| BOLT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (30.5 M) | (60.7 M) | (98.6 M) | (88.1 M) | (88.1 M) | (88.1 M) | (79.3 M) | (83.3 M) |
| COCP | (23.8 M) | (23.8 M) | (23.8 M) | (23.8 M) | (99 K) | (50.1 M) | (74.9 M) | (613 K) | (49 M) | (48.2 M) | (9.6 M) | (14.2 M) | (38.8 M) | (38.8 M) | (38.8 M) | (35 M) | (36.7 M) |
| EVGN | 645 K | 645 K | (8.9 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (18.1 M) | (23.4 M) | (27.8 M) | (26.6 M) | (26.6 M) | (26.6 M) | (24 M) | (25.2 M) |
| LYRA | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (6.1 M) | (16.6 M) | (22.1 M) | (43.5 M) | (55.3 M) | (55.3 M) | (55.3 M) | (49.8 M) | (47.3 M) |
Aptorum Group and related stocks such as Marker Therapeutics, Mustang Bio, and Cingulate Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Aptorum Group Ltd | APM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 17 Hanover Square, |
| Exchange | NASDAQ Exchange |
USD 0.81
Check out Aptorum Group Performance and Aptorum Group Correlation. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Aptorum Group technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.